Wedbush Downgrades Aimmune Therapeutics (AIMT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 66
Join SI Premium – FREE
Wedbush analyst Liana Moussatos downgraded Aimmune Therapeutics (NASDAQ: AIMT) from Outperform to Neutral with a price target of $34.50 (from $66.00).
For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.
Shares of Aimmune Therapeutics closed at $12.60 yesterday.
You May Also Be Interested In
- Constellation Brands (STZ) PT Lowered to $155 at Goldman Sachs
- Yorkville Ives Starts Walt Disney (DIS) at Outperform
- Nomura/Instinet Downgrades Workman Co Ltd (7564:JP) (WKISF) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
